n(g),n(g')-dimethyl-l-arginine has been researched along with Polycystic Ovary Syndrome in 22 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.
| Excerpt | Relevance | Reference |
|---|---|---|
| " ADMA, homocysteine, high sensitive C-reactive protein (hs-CRP) and homeostasis model assessment estimate of insulin resistance (HOMA-IR) were investigated." | 9.15 | Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. ( Aydin, M; Batioglu, S; Erdogan, G; Kilic, S; Yilmaz, N; Zulfikaroglu, E, 2011) |
| "To evaluate retinol-binding protein 4 (RBP4), leptin, and asymmetric dimethylarginine (ADMA) levels in young women with polycystic ovary syndrome (PCOS) and to investigate their relationship with each other and with clinical, metabolic, and hormonal parameters." | 9.15 | Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome. ( Adali, E; Bugdayci, G; Ilhan, GA; Kolusari, A; Yildizhan, B; Yildizhan, R, 2011) |
| "Our study was undertaken to evaluate the levels of asymmetric dimethyl-arginine (ADMA) in a group of patients affected with polycystic ovary syndrome (PCOS)--under ethinyl estradiol-cyproterone acetate treatment or not--as compared with a group of healthy controls." | 7.80 | Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome. ( Akdeniz, D; Carlioglu, A; Gumus, II; Karakurt, F; Kaygusuz, I; Uz, B, 2014) |
| "To evaluate the asymmetric dimethylarginine (ADMA) and nitric oxide (NO) levels in obese and lean patients with polycystic ovarian syndrome (PCOS) and find out their relation with hormonal and metabolic parameters." | 7.77 | Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome. ( Engin-Üstün, Y; Kafkasli, A; Kali, Z; Karabulut, AB; Meydanli, M; Turan, F; Türkçüoğlu, I, 2011) |
| "To evaluate endothelial function via serum asymmetric dimethylarginine (ADMA) levels, paraoxonase 1 (PON1) activity, and brachial artery flow-mediated dilatation (FMD) in women with polycystic ovary syndrome (PCOS)." | 7.77 | Serum paraoxonase 1 activity, asymmetric dimethylarginine levels, and brachial artery flow-mediated dilatation in women with polycystic ovary syndrome. ( Bayrak, A; Bayrak, T; Cakir, E; Noyan, V; Sagsoz, N; Soyman, Z; Tulmac, M; Yucel, A, 2011) |
| "To evaluate the plasma asymmetric dimethyl arginine (ADMA) levels and carotid intima-media thickness (IMT) in patients with polycystic ovary syndrome (PCOS)." | 7.76 | Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. ( Ciftci, O; Demirag, NG; Ertugrul, D; Kulaksizoglu, M; Kulaksizoglu, S; Pamuk, BO; Torun, AN; Yildirim, E, 2010) |
| "The aim of this study was to investigate serum leptin, oxidized low density lipoprotein (ox-LDL) and asymmetric dimethylarginine (ADMA) levels and their interaction with dyslipidaemia in adolescents with polycystic ovary syndrome (PCOS)." | 7.74 | Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. ( Biberoğlu, G; Bideci, A; Camurdan, MO; Cinaz, P; Demirel, F; Hasanoğlu, A; Yesilkaya, E, 2007) |
| " In this study, therefore, we aimed (1) to determine the circulating ADMA concentrations in 44 women with PCOS and 22 age- and BMI-matched healthy controls, (2) to evaluate its correlations with insulin resistance, gonadotrophins, and androgen secretion, and (3) to compare effects of metformin and ethinyl estradiol-cyproterone acetate (EE/CPA) treatments on circulating ADMA concentrations." | 7.74 | Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). ( Baser, I; Dede, M; Erbil, MK; Kenar, L; Oktenli, C; Ozgurtas, T; Sanisoglu, SY; Tapan, S; Yenen, MC; Yesilova, Z, 2008) |
| "Metformin treatment led to improvement of hormonal and metabolic parameters and decreased ADMA levels possibly independent of BMI and metabolic changes." | 5.35 | Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. ( Heutling, D; Kaltwasser, P; Kleinstein, J; Krzyzanowska, K; Lehnert, H; Mittermayer, F; Nickel, I; Randeva, H; Schernthaner, G; Schulz, H; Westphal, S; Wolzt, M, 2008) |
| " At Weeks 0 and 20, weight, markers of endothelial function [vascular cell adhesion molecule-1 (sVCAM-1), inter-cellular adhesion molecule-1 (sICAM-1), plasminogen activator inhibitor-1 (PAI-1) and asymmetric dimethylarginine (ADMA)], insulin resistance and hormonal profile were assessed." | 5.16 | The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome. ( Brinkworth, GD; Buckley, JD; Clifton, PM; Noakes, M; Norman, RJ; Thomson, RL, 2012) |
| " ADMA, homocysteine, high sensitive C-reactive protein (hs-CRP) and homeostasis model assessment estimate of insulin resistance (HOMA-IR) were investigated." | 5.15 | Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. ( Aydin, M; Batioglu, S; Erdogan, G; Kilic, S; Yilmaz, N; Zulfikaroglu, E, 2011) |
| "To evaluate retinol-binding protein 4 (RBP4), leptin, and asymmetric dimethylarginine (ADMA) levels in young women with polycystic ovary syndrome (PCOS) and to investigate their relationship with each other and with clinical, metabolic, and hormonal parameters." | 5.15 | Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome. ( Adali, E; Bugdayci, G; Ilhan, GA; Kolusari, A; Yildizhan, B; Yildizhan, R, 2011) |
| "In polycystic ovary syndrome, metformin improves insulin resistance, inflammatory markers, and endothelial function." | 5.14 | Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. ( Hutchison, SK; McGrath, BP; Meyer, C; Moran, LJ; Teede, HJ; Zoungas, S, 2010) |
| "Our study was undertaken to evaluate the levels of asymmetric dimethyl-arginine (ADMA) in a group of patients affected with polycystic ovary syndrome (PCOS)--under ethinyl estradiol-cyproterone acetate treatment or not--as compared with a group of healthy controls." | 3.80 | Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome. ( Akdeniz, D; Carlioglu, A; Gumus, II; Karakurt, F; Kaygusuz, I; Uz, B, 2014) |
| " Plasma asymmetric dimethylarginine (ADMA) levels, serum nitric oxide (NO) levels, and homeostatic model assessment of insulin resistance (HOMA-IR) rates were measured in both the patient and control groups." | 3.80 | Endothelial dysfunction and insulin resistance in young women with polycystic ovarian syndrome. ( Bayraktar, N; Göktaş, T; Gülcan Kurt, Y; Güler, İ; Hımmetoğlu, MÖ; Kiliç, N; Taner, MZ; Taşlipinar, A; Yaman, H; Yavuz Taşlipinar, M, 2014) |
| " The effect of weight loss on the vascular inflammatory markers plasminogen activator inhibitor-1 (PAI-1), asymmetric dimethylarginine (ADMA), soluble vascular cell adhesion molecule-1 (sVCAM-1) and intracellular adhesion molecule-1 (sICAM-1) is unknown." | 3.78 | Weight loss and vascular inflammatory markers in overweight women with and without polycystic ovary syndrome. ( Clifton, PM; Moran, LJ; Noakes, M; Norman, RJ; Wittert, GA, 2012) |
| "To evaluate the asymmetric dimethylarginine (ADMA) and nitric oxide (NO) levels in obese and lean patients with polycystic ovarian syndrome (PCOS) and find out their relation with hormonal and metabolic parameters." | 3.77 | Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome. ( Engin-Üstün, Y; Kafkasli, A; Kali, Z; Karabulut, AB; Meydanli, M; Turan, F; Türkçüoğlu, I, 2011) |
| "To evaluate endothelial function via serum asymmetric dimethylarginine (ADMA) levels, paraoxonase 1 (PON1) activity, and brachial artery flow-mediated dilatation (FMD) in women with polycystic ovary syndrome (PCOS)." | 3.77 | Serum paraoxonase 1 activity, asymmetric dimethylarginine levels, and brachial artery flow-mediated dilatation in women with polycystic ovary syndrome. ( Bayrak, A; Bayrak, T; Cakir, E; Noyan, V; Sagsoz, N; Soyman, Z; Tulmac, M; Yucel, A, 2011) |
| "To evaluate the plasma asymmetric dimethyl arginine (ADMA) levels and carotid intima-media thickness (IMT) in patients with polycystic ovary syndrome (PCOS)." | 3.76 | Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. ( Ciftci, O; Demirag, NG; Ertugrul, D; Kulaksizoglu, M; Kulaksizoglu, S; Pamuk, BO; Torun, AN; Yildirim, E, 2010) |
| "The aim of this study was to investigate serum leptin, oxidized low density lipoprotein (ox-LDL) and asymmetric dimethylarginine (ADMA) levels and their interaction with dyslipidaemia in adolescents with polycystic ovary syndrome (PCOS)." | 3.74 | Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. ( Biberoğlu, G; Bideci, A; Camurdan, MO; Cinaz, P; Demirel, F; Hasanoğlu, A; Yesilkaya, E, 2007) |
| " In this study, therefore, we aimed (1) to determine the circulating ADMA concentrations in 44 women with PCOS and 22 age- and BMI-matched healthy controls, (2) to evaluate its correlations with insulin resistance, gonadotrophins, and androgen secretion, and (3) to compare effects of metformin and ethinyl estradiol-cyproterone acetate (EE/CPA) treatments on circulating ADMA concentrations." | 3.74 | Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). ( Baser, I; Dede, M; Erbil, MK; Kenar, L; Oktenli, C; Ozgurtas, T; Sanisoglu, SY; Tapan, S; Yenen, MC; Yesilova, Z, 2008) |
| "Metformin treatment led to improvement of hormonal and metabolic parameters and decreased ADMA levels possibly independent of BMI and metabolic changes." | 1.35 | Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. ( Heutling, D; Kaltwasser, P; Kleinstein, J; Krzyzanowska, K; Lehnert, H; Mittermayer, F; Nickel, I; Randeva, H; Schernthaner, G; Schulz, H; Westphal, S; Wolzt, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 15 (68.18) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Li, T | 1 |
| Zhang, T | 1 |
| Wang, H | 1 |
| Zhang, Q | 1 |
| Gao, H | 1 |
| Liu, R | 1 |
| Yin, C | 1 |
| Rashidi, BH | 1 |
| Mohammad Hosseinzadeh, F | 1 |
| Alipoor, E | 1 |
| Asghari, S | 1 |
| Yekaninejad, MS | 1 |
| Hosseinzadeh-Attar, MJ | 1 |
| Javn, SB | 1 |
| Thomas, S | 1 |
| Ramachandran, S | 1 |
| Loganathan, S | 1 |
| Sundari, M | 1 |
| Mala, K | 1 |
| Krishna, MB | 1 |
| Joseph, A | 1 |
| Thomas, PL | 1 |
| Dsilva, B | 1 |
| Pillai, SM | 1 |
| Laloraya, M | 1 |
| Karakurt, F | 1 |
| Carlioglu, A | 1 |
| Kaygusuz, I | 1 |
| Gumus, II | 1 |
| Uz, B | 1 |
| Akdeniz, D | 1 |
| Yavuz Taşlipinar, M | 1 |
| Kiliç, N | 1 |
| Bayraktar, N | 1 |
| Güler, İ | 1 |
| Gülcan Kurt, Y | 1 |
| Göktaş, T | 1 |
| Taner, MZ | 1 |
| Hımmetoğlu, MÖ | 1 |
| Yaman, H | 1 |
| Taşlipinar, A | 1 |
| Teede, HJ | 2 |
| Meyer, C | 1 |
| Hutchison, SK | 1 |
| Zoungas, S | 1 |
| McGrath, BP | 1 |
| Moran, LJ | 3 |
| Pamuk, BO | 1 |
| Torun, AN | 1 |
| Kulaksizoglu, M | 1 |
| Ertugrul, D | 1 |
| Ciftci, O | 1 |
| Kulaksizoglu, S | 1 |
| Yildirim, E | 1 |
| Demirag, NG | 1 |
| Türkçüoğlu, I | 1 |
| Engin-Üstün, Y | 1 |
| Turan, F | 1 |
| Kali, Z | 1 |
| Karabulut, AB | 1 |
| Meydanli, M | 1 |
| Kafkasli, A | 1 |
| Kilic, S | 1 |
| Yilmaz, N | 1 |
| Zulfikaroglu, E | 1 |
| Erdogan, G | 1 |
| Aydin, M | 1 |
| Batioglu, S | 1 |
| Soyman, Z | 1 |
| Noyan, V | 1 |
| Tulmac, M | 1 |
| Yucel, A | 1 |
| Sagsoz, N | 1 |
| Bayrak, T | 2 |
| Bayrak, A | 2 |
| Cakir, E | 2 |
| Yildizhan, R | 1 |
| Ilhan, GA | 1 |
| Yildizhan, B | 1 |
| Kolusari, A | 2 |
| Adali, E | 1 |
| Bugdayci, G | 1 |
| Cameron, JD | 1 |
| Strauss, BJ | 1 |
| Thomson, RL | 1 |
| Brinkworth, GD | 1 |
| Noakes, M | 2 |
| Clifton, PM | 2 |
| Norman, RJ | 2 |
| Buckley, JD | 1 |
| Dursun, P | 1 |
| Gültekin, M | 1 |
| Ozyurt, M | 1 |
| Zeyneloğlu, HB | 1 |
| Choi, YS | 1 |
| Yang, HI | 1 |
| Cho, S | 1 |
| Jung, JA | 1 |
| Jeon, YE | 1 |
| Kim, HY | 1 |
| Seo, SK | 1 |
| Lee, BS | 1 |
| Wittert, GA | 1 |
| Charitidou, C | 1 |
| Farmakiotis, D | 1 |
| Zournatzi, V | 1 |
| Pidonia, I | 1 |
| Pegiou, T | 1 |
| Karamanis, N | 1 |
| Hatzistilianou, M | 1 |
| Katsikis, I | 1 |
| Panidis, D | 1 |
| Demirel, F | 1 |
| Bideci, A | 1 |
| Cinaz, P | 1 |
| Camurdan, MO | 1 |
| Biberoğlu, G | 1 |
| Yesilkaya, E | 1 |
| Hasanoğlu, A | 1 |
| Heutling, D | 1 |
| Schulz, H | 1 |
| Nickel, I | 1 |
| Kleinstein, J | 1 |
| Kaltwasser, P | 1 |
| Westphal, S | 1 |
| Mittermayer, F | 1 |
| Wolzt, M | 1 |
| Krzyzanowska, K | 1 |
| Randeva, H | 1 |
| Schernthaner, G | 1 |
| Lehnert, H | 1 |
| Sattar, N | 1 |
| Nelson, SM | 1 |
| Ozgurtas, T | 1 |
| Oktenli, C | 1 |
| Dede, M | 1 |
| Tapan, S | 1 |
| Kenar, L | 1 |
| Sanisoglu, SY | 1 |
| Yesilova, Z | 1 |
| Yenen, MC | 1 |
| Erbil, MK | 1 |
| Baser, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Semaglutide Compared to Metformin in Obese Women With Polycystic Ovary Syndrome (PCOS): a Randomised Controlled Study (Semaglutide-PCOS Trial).[NCT05646199] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873] | Phase 4 | 42 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for n(g),n(g')-dimethyl-l-arginine and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Polycystic ovarian syndrome-associated cardiovascular complications: An overview of the association between the biochemical markers and potential strategies for their prevention and elimination.
Topics: Arginine; Biomarkers; Cardiovascular Diseases; Female; Glycation End Products, Advanced; Homocystein | 2017 |
6 trials available for n(g),n(g')-dimethyl-l-arginine and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Effects of Selenium Supplementation on Asymmetric Dimethylarginine and Cardiometabolic Risk Factors in Patients with Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Arginine; Cardiometabolic Risk Factors; Dietary Supplements; Double-Blind Method; | 2020 |
Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Topics: Adult; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; Contraceptives, Oral, Combined; Cont | 2010 |
Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment.
Topics: Adult; Arginine; Body Mass Index; Cardiovascular Diseases; Contraceptives, Oral; Female; Homocystein | 2011 |
Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome.
Topics: Adult; Arginine; Biomarkers; Female; Humans; Leptin; Obesity; Polycystic Ovary Syndrome; Prospective | 2011 |
The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome.
Topics: Adult; Arginine; Body Mass Index; Cardiovascular Diseases; Diet; Endothelium, Vascular; Exercise; Ex | 2012 |
The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Arginine; Cyproterone Acetate; Desogestrel; Drug Therapy, Combination; | 2008 |
15 other studies available for n(g),n(g')-dimethyl-l-arginine and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
The ADMA-DDAH1 axis in ovarian apoptosis of polycystic ovary syndrome.
Topics: Amidohydrolases; Animals; Apoptosis; Arginine; Dehydroepiandrosterone; Female; Humans; Polycystic Ov | 2023 |
Impaired Arginine Metabolism Coupled to a Defective Redox Conduit Contributes to Low Plasma Nitric Oxide in Polycystic Ovary Syndrome.
Topics: Amidohydrolases; Arginine; Argininosuccinate Lyase; Cationic Amino Acid Transporter 1; Female; Human | 2017 |
Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Arginine; Cholesterol, LDL; Cyproterone Acetate; Drug Combinations; Eth | 2014 |
Endothelial dysfunction and insulin resistance in young women with polycystic ovarian syndrome.
Topics: Adult; Arginine; Body Mass Index; Endothelium, Vascular; Female; Humans; Insulin Resistance; Nitric | 2014 |
Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters.
Topics: Adolescent; Adult; Arginine; Energy Metabolism; Female; Humans; Obesity; Polycystic Ovary Syndrome; | 2010 |
Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome.
Topics: Adolescent; Adult; Arginine; Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Female | 2011 |
Serum paraoxonase 1 activity, asymmetric dimethylarginine levels, and brachial artery flow-mediated dilatation in women with polycystic ovary syndrome.
Topics: Adult; Arginine; Aryldialkylphosphatase; Biomarkers; Blood Flow Velocity; Brachial Artery; Case-Cont | 2011 |
Vascular function in the diagnostic categories of polycystic ovary syndrome.
Topics: Adult; Arginine; C-Reactive Protein; Cardiovascular Diseases; Cross-Sectional Studies; Endothelium, | 2011 |
Paraoxonase lactonase activity (PON-HTLase), asymmetric dimethylarginine (ADMA) and platelet activating factor-acetylhydrolase (PAF-AH) activity in non-obese women with PCOS.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adolescent; Adult; Arginine; Aryldialkylphosphatase; | 2012 |
Serum asymmetric dimethylarginine, apelin, and tumor necrosis factor-α levels in non-obese women with polycystic ovary syndrome.
Topics: Apelin; Arginine; Body Mass Index; Case-Control Studies; Female; Humans; Hyperandrogenism; Intercell | 2012 |
Weight loss and vascular inflammatory markers in overweight women with and without polycystic ovary syndrome.
Topics: Adult; Arginine; Biomarkers; Cardiovascular Diseases; Female; Humans; Intercellular Adhesion Molecul | 2012 |
Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome.
Topics: Adolescent; Apolipoproteins B; Arginine; Biomarkers; Case-Control Studies; Cholesterol; Cholesterol, | 2007 |
Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment.
Topics: Adult; Androgens; Arginine; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Cr | 2008 |
Polycystic ovarian syndrome, biomarkers, and metformin: research, risk, and reality.
Topics: Arginine; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Risk Factors | 2008 |
Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS).
Topics: Adult; Androgens; Arginine; Body Mass Index; Case-Control Studies; Contraceptives, Oral; Cyproterone | 2008 |